NEURONETICS INC (STIM)       6.2  -0.04 (-0.64%)

6.2  -0.04 (-0.64%)

US64131A1051 - Common Stock


Fundamental Rating

2

Overall STIM gets a fundamental rating of 2 out of 10. We evaluated STIM against 221 industry peers in the Health Care Equipment & Supplies industry. Both the profitability and financial health of STIM have multiple concerns. STIM is quite expensive at the moment. It does show a decent growth rate.




Profitability

Profitability Rating

1

STIM's Return On Assets of -30.62% is in line with the rest of the industry. The industry average Return On Assets is -19.67%.
The profitability ratios for STIM are negative, so there is not much use analyzing them.

The Piotroski-F score of STIM is 3.00. This is a low score and indicates issues in the health and profitability of STIM.
VS Industry

ROA (-30.62%) VS Industry: 43% outperformed.

-771.54
117.69

Valuation

Valuation Rating

1

With a price book ratio of 2.68, STIM is valued correctly.
Compared to an average industry price book ratio of 2.62, STIM is valued in line with its industry peers.

STIM reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for STIM. No positive earnings are expected for the next year.
VS Industry

Price/Book (2.68) VS Industry: 49% outperformed.

1,098.53
0.06

Growth

Growth Rating

5

STIM shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 11.02%.
Measured over the past 5 years, STIM shows a quite strong growth in Revenue. The Revenue has been growing by 10.07% on average per year.
The Revenue is expected to grow by 14.64% on average over the next 5 years. This is quite good.

When comparing the Revenue growth rate of the last 5 years to the growth rate of the upcoming 5 years, we see that the growth is accelerating.
Based on estimates for the next 5 years, STIM will show a decrease in Earnings Per Share. The EPS will decrease by -2.27% on average per year.
The earnings per share for STIM have decreased strongly by -24.45% in the last year.

PastFuture
5Y3Y1Y1Y2Y3Y5Y
EPSN/A N/A -24.45% -38.21% -8.46% 9.14% -2.27%
Revenue10.07% 1.57% 11.02% 13.07% 15.76% 17.73% 14.64%

Health

Health Rating

3

STIM has a Current Ratio of 4.02. This indicates that STIM is financially healthy and has no problem in meeting its short term obligations.
A Quick Ratio of 3.68 indicates that STIM has no problem at all paying its short term obligations.
STIM has a Current Ratio comparable to the industry average, which is at 3.69.
STIM has a Quick Ratio comparable to the industry average, which is at 2.91.

Compared to an average industry Debt to Equity Ratio of 0.09, STIM is more dependent on financing than its industry peers.
STIM has an Altman-Z score of -1.82. This is a bad value and indicates that STIM is not financially healthy and even has some risk of bankruptcy.
When comparing the Altman-Z score of STIM to the average industry Altman-Z score of 1.87, STIM is less financially healthy than its industry peers.
The Piotroski-F score of STIM is 3.00. This is a low score and indicates issues in the health and profitability of STIM.
VS Industry

Debt/Equity (0.43) VS Industry: 27% outperformed.

336.87
0.00

Quick Ratio (3.68) VS Industry: 60% outperformed.

0.06
31.22

Current Ratio (4.02) VS Industry: 57% outperformed.

0.13
31.22

Altman-Z (-1.82) VS Industry: 32% outperformed.

-105.06
71.69

Dividend

Dividend Rating

0

STIM does not give a dividend.

STIM Daily chart

NEURONETICS INC6.2

NASDAQ:STIM (12/8/2022, 7:09:20 PM)-0.04 (-0.64%)

Chartmill FA Rating
GICS Sector Health Care
GICS IndustryGroup Health Care Equipment & Services
GICS Industry Health Care Equipment & Supplies
Earnings (Last) 11-08 2022-11-08/bmo Earnings (Next) 03-06 2023-03-06
Ins Owners 8.46% Inst Owners 63.6%
Market Cap 168.77M Analysts 80
Valuation
PE N/A Fwd PE N/A
PEG (NY) N/A PEG (5Y) N/A
P/S 2.72 P/B 2.68
EV/EBITDA N/A
Dividend
Dividend Yield N/A Dividend Growth N/A
DP N/A Ex-Date N/A
Growth
EPS 1Y -24.45% EPS 3Y N/A
EPS 5Y N/A EPS growth Q2Q 9.68%
EPS Next Y -38.21% EPS Next 2Y -8.46%
EPS Next 3Y 9.14% EPS Next 5Y -2.27%
Revenue growth 1Y 11.02% Revenue growth 3Y 1.57%
Revenue growth 5Y 10.07% Revenue growth Q2Q 19.56%
Revenue Next Year 13.07% Revenue Next 2Y 15.76%
Revenue Next 3Y 17.73% Revenue Next 5Y 14.64%
Health
Current Ratio 4.02 Quick Ratio 3.68
Altman-Z -1.82 F-Score 3
Debt/Equity 0.43 WACC 9.92%
ROIC/WACC N/A
Profitability
ROA -30.62% ROE N/A
ROICexgc N/A ROIC N/A
PM N/A OM N/A
Asset Turnover 0.52

Fundamental Stock Screener Links

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA